Results of ASCT in the treatment of FL
| Author . | No. of patients . | Status at time of transplantation . | TBI/CY . | Follow-up . | TRM, % . | CR, % . | Relapse, % . | CR+, % . |
|---|---|---|---|---|---|---|---|---|
| Van Biesen et al154 | 10 | Refractory 80% | 8 of 10 | 2.5 y | 20 | 80 | 0 | 80 |
| Van Biesen et al155 | 113 | Stage IV 83% Poor PS 29% Refractory 37% | 86 of 113 | 3 y | 40 | 49 | 16 | 49 |
| Mandigers et al156 | 15 | Early relapse | 15 of 15 | 3 y | 33 | 67 | 13 | 67 |
| T depleted | 2 after DLI | |||||||
| Resistant disease | ||||||||
| Stein et al157 | 15 | Resistant disease 27% BM involvement 73% | 14 of 15 | 5 y | 53 | 46 | 20 | 26 |
| Verdonck et al10 | 15 | Refractory disease 46% BM involvement 93% T depleted | 15 of 15 | 25 mo | 27 | 100 | 0 | 70 |
| Toze et al158 | 16 | Resistant disease 31% Stage IV 81% | NE | 2.4 y | 25 | 76 | 0 | 50 |
| Forrest et al159 | 24 | Relapse 95% Refractory 5% Stage IV 66% | 3% 79% busulfan CY | 25 mo | 21 | 79 | 0 | 79 |
| Cull et al160 | 12 | BM involvement 83% Poor prognosis 8% Pancytopenia 8% | 0% DexaBEAM CAMPATH-1G | 12 mo | 8 | 83 | 8 | 66 1 after DLI |
| Author . | No. of patients . | Status at time of transplantation . | TBI/CY . | Follow-up . | TRM, % . | CR, % . | Relapse, % . | CR+, % . |
|---|---|---|---|---|---|---|---|---|
| Van Biesen et al154 | 10 | Refractory 80% | 8 of 10 | 2.5 y | 20 | 80 | 0 | 80 |
| Van Biesen et al155 | 113 | Stage IV 83% Poor PS 29% Refractory 37% | 86 of 113 | 3 y | 40 | 49 | 16 | 49 |
| Mandigers et al156 | 15 | Early relapse | 15 of 15 | 3 y | 33 | 67 | 13 | 67 |
| T depleted | 2 after DLI | |||||||
| Resistant disease | ||||||||
| Stein et al157 | 15 | Resistant disease 27% BM involvement 73% | 14 of 15 | 5 y | 53 | 46 | 20 | 26 |
| Verdonck et al10 | 15 | Refractory disease 46% BM involvement 93% T depleted | 15 of 15 | 25 mo | 27 | 100 | 0 | 70 |
| Toze et al158 | 16 | Resistant disease 31% Stage IV 81% | NE | 2.4 y | 25 | 76 | 0 | 50 |
| Forrest et al159 | 24 | Relapse 95% Refractory 5% Stage IV 66% | 3% 79% busulfan CY | 25 mo | 21 | 79 | 0 | 79 |
| Cull et al160 | 12 | BM involvement 83% Poor prognosis 8% Pancytopenia 8% | 0% DexaBEAM CAMPATH-1G | 12 mo | 8 | 83 | 8 | 66 1 after DLI |
TRM indicates transplantation-related mortality; CR, complete response after BMT; CR+, complete response rate at the median follow-up; TBI, total body irradiation; BM, bone marrow; DLI, donor leucocyte infusion; PS, performance status; and CY, cyclophosphamide.